Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Considerations for Drug Development in Myelodysplastic Syndromes.
Sekeres MA, Kim N, DeZern AE, Norsworthy KJ, Garcia JS, de Claro RA, Theoret MR, Jen EY, Ehrlich LA, Zeidan AM, Komrokji RS. Sekeres MA, et al. Among authors: garcia js. Clin Cancer Res. 2023 Jul 14;29(14):2573-2579. doi: 10.1158/1078-0432.CCR-22-3348. Clin Cancer Res. 2023. PMID: 36688922 Free PMC article.
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.
Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Harrison CN, et al. Among authors: garcia js. J Clin Oncol. 2022 May 20;40(15):1671-1680. doi: 10.1200/JCO.21.02188. Epub 2022 Feb 18. J Clin Oncol. 2022. PMID: 35180010 Free PMC article. Clinical Trial.
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng WH, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia-Manero G. Zeidan AM, et al. Among authors: garcia js, garcia manero g. Am J Hematol. 2023 Feb;98(2):272-281. doi: 10.1002/ajh.26771. Epub 2022 Nov 10. Am J Hematol. 2023. PMID: 36309981 Free PMC article. Clinical Trial.
Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates.
Chen EC, Gandler H, Tošić I, Fell GG, Fiore A, Pozdnyakova O, DeAngelo DJ, Galinsky I, Luskin MR, Wadleigh M, Winer ES, Leonard R, O'Day K, de Jonge A, Neuberg D, Look AT, Stone RM, Frank DA, Garcia JS. Chen EC, et al. Among authors: garcia js. Clin Cancer Res. 2023 Mar 1;29(5):878-887. doi: 10.1158/1078-0432.CCR-22-2540. Clin Cancer Res. 2023. PMID: 36534523 Free PMC article.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Zeidan AM, Platzbecker U, Bewersdorf JP, Stahl M, Adès L, Borate U, Bowen D, Buckstein R, Brunner A, Carraway HE, Daver N, Díez-Campelo M, de Witte T, DeZern AE, Efficace F, Garcia-Manero G, Garcia JS, Germing U, Giagounidis A, Griffiths EA, Hasserjian RP, Hellström-Lindberg E, Iastrebner M, Komrokji R, Kulasekararaj AG, Malcovati L, Miyazaki Y, Odenike O, Santini V, Sanz G, Scheinberg P, Stauder R, van de Loosdrecht AA, Wei AH, Sekeres MA, Fenaux P. Zeidan AM, et al. Among authors: garcia js, garcia manero g. Blood. 2023 Apr 27;141(17):2047-2061. doi: 10.1182/blood.2022018604. Blood. 2023. PMID: 36724453 Free article.
Prospects for Venetoclax in Myelodysplastic Syndromes.
Garcia JS. Garcia JS. Hematol Oncol Clin North Am. 2020 Apr;34(2):441-448. doi: 10.1016/j.hoc.2019.10.005. Epub 2019 Dec 11. Hematol Oncol Clin North Am. 2020. PMID: 32089221 Review.
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Konopleva M, et al. Among authors: garcia js. Clin Cancer Res. 2022 Jul 1;28(13):2744-2752. doi: 10.1158/1078-0432.CCR-21-3405. Clin Cancer Res. 2022. PMID: 35063965 Free PMC article.
Defining disease modification in myelofibrosis in the era of targeted therapy.
Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, Oh ST, Passamonti F, Döhner K, Mead AJ. Pemmaraju N, et al. Among authors: garcia js. Cancer. 2022 Jul 1;128(13):2420-2432. doi: 10.1002/cncr.34205. Epub 2022 May 2. Cancer. 2022. PMID: 35499819 Free PMC article. Review.
Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
Wheeler EC, Martin BJE, Doyle WC, Neaher S, Conway CA, Pitton CN, Gorelov RA, Donahue M, Jann JC, Abdel-Wahab O, Taylor J, Seiler M, Buonamici S, Pikman Y, Garcia JS, Belizaire R, Adelman K, Tothova Z. Wheeler EC, et al. Among authors: garcia js. Sci Transl Med. 2024 Jan 3;16(728):eade2774. doi: 10.1126/scitranslmed.ade2774. Epub 2024 Jan 3. Sci Transl Med. 2024. PMID: 38170787
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival.
Garcia JS, Swords RT, Roboz GJ, Jacoby MA, Garcia-Manero G, Hong WJ, Yang X, Zhou Y, Platzbecker U, Steensma DP, Wolff JE, Fenaux P. Garcia JS, et al. Among authors: garcia manero g. Leuk Res. 2021 May;104:106555. doi: 10.1016/j.leukres.2021.106555. Epub 2021 Mar 2. Leuk Res. 2021. PMID: 33705966 Free article.
190 results